Pfizer

Mar 12, 2021

More than 100 million people are living with one or the other form of Chronic Pain in the USA, says the Institute of Medicine. The available treatments to tackle cancer, as well as non-cancer pain, include nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, or combinations of opioids and non-narc...

Jan 26, 2021

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Jan 05, 2021

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon Pfizer and Opko had joined hands in 2014 to develop somatrogon, a pediatric growth hormone deficiency (GHD) drug. It comprises the natural sequence of growth hormone and a copy of the C-terminal peptid...

Dec 29, 2020

A USD 4.2 Billion Myovant/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health.  Relugolix is a once-daily, oral gonadotropin-rel...

Dec 15, 2020

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development...

Nov 19, 2020

Pfizer succeeds COVID-19 vaccine safety milestone Pfizer prepares to file its COVID-19 vaccine for emergency use authorization (EUA) after succeeding a key safety breakthrough. Pfizer now has the median two-month follow-up data needed for securing EUA from the FDA, moving a step closer for bringing its vaccine t...

Nov 10, 2020

Pfizer's COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, the pharma titan, Pfizer, announced that its COVID-19 vaccine is more than 90% effective in preventing coronavirus infection. Tedros Adhanom Ghebrey...

Oct 01, 2020

The immune cells of the brain could treat neurodegenerative diseases Human behavior relies on the stimulation and inhibition of neurons, and scientists have long considered that neurons are mainly responsible for maintaining this circuit of activity in balance. However, now, a research team led by the Icahn Scho...

Sep 10, 2020

Pfizer, BioNTech report shows the immune response in animals to COVID-19  Pfizer and its partner BioNTech have five potential COVID-19 vaccines in clinical trials, each based on a different mRNA format. The companies are now exhibiting that the most advanced candidate, BNT162b2, performed well in trials in ...

Aug 03, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. More than half of the cancer patients suffer from cachexia, and over 30% of the cancer patients succumb to death due to complications that arise from cachexi...